ClinicalTrials.gg
CompletedNCT01263899Updated Apr 20, 2012

A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

A Phase 2 interventional study of SB1518 in Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma, sponsored by S*BIO. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-20.

Sponsored by S*BIO · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
482nd of 818
28 · median 35
Started
2010
with 47 others
Phase 2
346 of 970
30 open now
Registered
563rd of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 482nd largest by enrollment of the 818 interventional ones that give a count, is one of 48 that started in 2010, is one of 346 in phase 2, and was the 563rd registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).

03

Conditions studied

  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Indolent Lymphoma

Keywords

  • Lymphoid malignancies
  • Hodgkin lymphoma
  • Mantle Cell Lymphoma
  • Indolent Lymphoma
  • SB1518
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with documented diagnosis of one of the following lymphoid :
  • Hodgkin Lymphoma;
  • Mantle Cell Lymphoma;
  • Indolent Lymphoma (including follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma);
  • Patients must have received at least one prior treatment regimen; patients with Hodgkin Lymphoma must have received an stem cell transplant, refused or been deemed ineligible for stem cell transplant;
  • Able to understand and willing to sign the form.

Exclusion criteria

Exclusion Criteria:

  • Any histology other than Hodgkin Lymphoma, Mantle Cell Lymphoma or Indolent Lymphoma;
  • History of or active Central Nervous System (CNS) ;
  • Active (GVHD);
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    SB1518

    Drug: SB1518

Interventions

  • DrugSB1518

    SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.

06

What researchers measure

Primary outcomes

  1. Assess overall tumor response of SB1518 by CT/FDG-PET scan and bone marrow biopsy as applicable as a measure of efficacy

    Outcome Measure - To assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphophasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).

    Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication

Secondary outcomes

  1. Assess durability of response

    To assess the durability of response following SB1518 treatment in patients with advanced lymphoid malignancies.

    Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication

  2. Assess number of patients with adverse events as a measure of safety and tolerability

    To assess the safety and tolerability of SB1518 administered orally once daily in patients with advanced lymphoid malignancies.

    Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication

07

Study locations

5 sites
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Weill Medical College of Cornell
    New York, New York 10021, United States
  • University of Rochester James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • MD Anderson Cancer Canter
    Houston, Texas 77030, United States
  • University of British Columbia
    Vancouver, British Columbia V5Z 4E6, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 21, 2010
Start
Dec 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Apr 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01263899
Lead sponsor
S*BIO
Responsible party
Sponsor
First posted
Dec 21, 2010
Start date
Dec 2010
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Apr 20, 2012

Study contacts

Anas Younes, MD
principal investigator · MD Anderson Cancer Center at University of Texas, Houston
Jonathan Friedberg, MD
principal investigator · University of Rochester James P. Wilmot Cancer Center
Peter Martin, MD
principal investigator · Weill Medical College of Cornell University
Julie Vose, MD
principal investigator · University of Nebraska
Richard Klasa, MD
principal investigator · British Columbia Cancer Center - Vancouver Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion